Polyclonal Antibody to Octamer Binding Transcription Factor 4 (OCT4)
| Code | Size | Price |
|---|
| PAA424Hu01-20ul | 20ul | £81.00 |
Quantity:
| PAA424Hu01-100ul | 100ul | £148.00 |
Quantity:
| PAA424Hu01-200ul | 200ul | £199.00 |
Quantity:
| PAA424Hu01-1ml | 1ml | £451.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
POU5F1; OCT3; OTF3; OTF4; Octamer-4; POU Domain Class 5 Transcription Factor 1; POU Class 5 Homoeobox 1; Octamer-binding protein 3
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Octamer Binding Transcription Factor 4
Reactivity:
Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
https://www.research-collection.ethz.ch/bitstream/handle/20.500.11850/351146/1/PhD_Thesis_escibona.pdf;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Octamer Binding Transcription Factor 4 (OCT4) | RPA424Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||